VCEL · XBRL financial data

Vericel financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VCEL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	124,179	156,184	164,365	197,516	237,224	276,259
Revenue from contracts with customers	121,968	153,075	163,698	197,516	237,224	276,259
Cost of goods and services sold	39,951	50,159	54,577	61,940	65,117	70,660
Gross profit	84,228	106,025	109,788	135,576	172,107	205,599
Research and development	13,020	16,287	19,943	21,042	24,797	27,563
Selling, general and administrative	68,836	97,592	106,903	120,998	142,791	166,992
General and administrative	—	—	45,977	51,991	60,649	76,790
Total operating expenses	81,856	113,879	126,846	142,040	167,588	194,555
Operating income (loss)	2,372	(7,854)	(17,058)	(6,464)	4,519	11,044
Interest income	691	224	1,341	4,632	6,410	7,007
Interest expense	13	4	366	600	614	630
Other income (expense)	(6)	52	95	64	195	(44)
Income tax expense (benefit)	180	(111)	721	814	148	859
Net income (loss)	2,864	(7,471)	(16,709)	(3,182)	10,362	16,518
Earnings per share, basic USD per share	0.06	(0.16)	(0.35)	(0.07)	0.21	0.33
Earnings per share, diluted USD per share	0.06	(0.16)	(0.35)	(0.07)	0.20	0.32
Weighted average shares, basic thousands of shares	45,221	46,472	47,130	47,590	48,848	50,340
Weighted average shares, diluted thousands of shares	47,282	46,472	47,130	47,590	51,679	52,151

Fiscal years (VCEL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	33,620	68,330	51,067	69,088	74,520	100,092
Short-term investments	42,187	35,068	68,471	40,469	41,693	37,407
Marketable securities, non-current	24,099	25,687	19,962	25,283	39,880	61,395
Accounts receivable	34,504	37,437	46,539	58,356	61,375	84,634
Inventory	9,356	13,381	15,986	13,087	17,373	17,560
Total current assets	123,560	158,462	186,866	205,631	212,777	247,437
Right-of-use asset	50,105	45,720	41,535	73,462	70,098	64,774
Total assets	205,608	243,705	273,003	353,657	432,722	487,969
Accounts payable	6,755	9,016	16,930	22,347	23,848	15,828
Accrued liabilities	11,293	14,045	16,190	17,215	17,065	19,236
Total current liabilities	22,483	26,052	37,463	45,749	50,286	49,149
Lease liability, non-current	48,789	47,147	43,268	81,856	89,593	82,284
Total liabilities	71,348	73,243	80,731	127,705	140,755	133,329
Accumulated deficit	(375,815)	(383,286)	(399,995)	(403,177)	(392,815)	(376,297)
Total stockholders' equity	134,260	170,462	192,272	225,952	291,967	354,640
Total liabilities and equity	205,608	243,705	273,003	353,657	432,722	487,969
Common shares outstanding (cover page) thousands of shares	45,955	46,968	47,364	48,290	49,970	50,763

Fiscal years (VCEL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	2,864	(7,471)	(16,709)	(3,182)	10,362	16,518
Stock-based compensation	13,843	34,322	37,183	32,325	36,495	38,767
Depreciation and amortization	2,383	3,000	3,981	4,632	5,504	11,544
Net cash from operating activities	17,572	29,040	17,687	35,311	58,163	51,910
Purchases of property and equipment	2,626	7,915	7,596	20,013	63,974	27,162
Net cash from investing activities	(17,160)	(3,501)	(36,206)	(3,130)	(79,034)	(43,937)
Proceeds from issuing common stock	—	—	—	6,000	24,516	13,934
Net cash from financing activities	6,441	9,171	1,045	3,618	19,054	7,070
Net change in cash	6,853	34,710	(17,474)	35,799	(1,817)	15,043

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Vericel	125,358	77,457	16,191*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Avadel Pharmaceuticals	79,813	77,467	22,205*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Recursion Pharmaceuticals	549,853	18,552	(77,406)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026
Bausch Health Companies	2,485,000	2,941,000	814,000*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Acadia Pharmaceuticals	384,985	307,959	100,781*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Agios Pharmaceuticals	99,647	44,745	(57,312)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117,436	not reported	1,115*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Biocryst Pharmaceuticals	96,971	180,292	32,983*	257.3M	—	Q3 FY26 10-QSep 30, 2026
Xenon Pharmaceuticals	119,527	not reported	(95,390)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.